Linked Life Data

11784625

Source:http://linkedlifedata.com/resource/pubmed/id/11784625

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9299
pubmed:dateCreated
2002-1-10
pubmed:abstractText
The plasma concentration of asymmetrical dimethylarginine (ADMA), an inhibitor of nitric-oxide synthase, which has been linked to endothelial dysfunction and atherosclerosis in the general population, is raised in patients with end-stage renal disease and could contribute to the high cardiovascular risk in patients with chronic renal failure. We investigated the relation between cardiovascular risk factors and plasma ADMA concentration in a cohort of haemodialysis patients (n=225), and tested the predictive power of ADMA for mortality and cardiovascular outcomes.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0140-6736
pubmed:author
pubmed:issnType
Print
pubmed:volume
358
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2113-7
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:articleTitle
Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.
pubmed:affiliation
CNR Centre of Clinical Physiology and Renal Unit, C, Reggio, Italy.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't